Core Viewpoint - The company announced a significant milestone in the development of its candidate drug CBT-004, with a meeting scheduled with the FDA to discuss the next steps in clinical trials and new drug application requirements [1][2]. Group 1: Clinical Trial Details - The company’s wholly-owned subsidiary, Cloudbreak Therapeutics LLC, is set to hold a post-phase 2 clinical trial meeting with the FDA on December 10, 2025 [1]. - CBT-004 is a potential first-in-class ophthalmic drug that targets vascular endothelial growth factor receptors and platelet-derived growth factor receptors, aimed at treating vascularized eyelid lesions [1]. - The phase 2 clinical trial for CBT-004 began in December 2023 and was completed in May 2025, showing safety and good tolerability among participants, achieving primary and several secondary endpoints [1]. Group 2: Future Development Plans - The upcoming meeting is crucial for discussing the potential development of a phase 3 clinical trial and the requirements for a new drug application [2]. - The company plans to issue further announcements to keep shareholders and potential investors updated on the latest developments in its business [2].
拨康视云-B(02592)：Cloudbreak USA排定于12月10日与美国食品及药物管理局正式举行第2期临床试验后会议